Kåre Schultz, Teva CEO (Christopher Goodney/Bloomberg via Getty Images)

Te­va reach­es $100M set­tle­ment with Rhode Is­land for decade of an­ti-nar­cot­ic drugs and $21M cash

Kåre Schultz, the top dog at Te­va Phar­ma­ceu­ti­cals, said last month on a Q4 call that the phar­ma gi­ant was con­fi­dent it could reach a na­tion­wide set­tle­ment over its role in the US opi­oid epi­dem­ic with­in a year’s time.

While to­day is not that day, Te­va can add one more state to the list of set­tle­ments the com­pa­ny has reached with in­di­vid­ual states.

The phar­ma an­nounced yes­ter­day that Te­va’s US sub­sidiary and Rhode Is­land at­tor­ney gen­er­al Pe­ter Neron­ha reached an agree­ment that would set­tle all of the state’s claims against Te­va re­lat­ed to the gener­ic play­er’s role in the US opi­oid epi­dem­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.